Dyne Therapeutics, Inc. (DYN)

Market Cap	986.63M
Revenue (ttm)	n/a
Net Income (ttm)	-367.13M
Shares Out	113.67M
EPS (ttm)	-3.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,320,648
Open	8.73
Previous Close	9.52
Day's Range	8.41 - 9.23
52-Week Range	6.36 - 47.45
Beta	1.16
Analysts	Strong Buy
Price Target	43.60 (+402.3%)
Earnings Date	Aug 11, 2025

About DYN

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and i...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2020
• Employees: 191
• Stock Exchange: NASDAQ
• Ticker Symbol: DYN
• Website: https://www.dyne-tx.com

Analyst Summary

According to 15 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price target is $43.6, which is an increase of 402.30% from the latest price.

Price Target

$43.6

(402.30% upside)

Analyst Consensus: Strong Buy